RxDoctor Payments Data

Maureen Allen

Physician Assistant · Greensboro, ALNPI 1275992513

Payments from drug & device makers

$742in general payments, 2019–2025

Across 40 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • Novartis$130
  • Johnson & Johnson$75
  • AbbVie$49
  • AstraZeneca$37
  • Vanda Pharmaceuticals Inc.$36
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742 in reported general payments places this provider in the 60th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$6,259
Medicare patients
65
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$111,255
FarxigaDapagliflozin Propanediol68$78,348
JardianceEmpagliflozin48$35,322
RybelsusSemaglutide22$30,259
MounjaroTirzepatide18$20,414
EliquisApixaban18$20,338
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$15,572
XareltoRivaroxaban12$14,456
JanuviaSitagliptin Phosphate13$11,918
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,815
Tresiba Flextouch U-100Insulin Degludec20$9,675
InvokanaCanagliflozin13$8,506
MyrbetriqMirabegron11$8,430
Albuterol Sulfate HfaAlbuterol Sulfate189$5,222
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$277$141,514103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$37$96,79394 claims
Johnson & JohnsonXarelto, Invokana$75$22,96125 claims
Lilly USA, LLCMounjaro$17$20,41418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Greensboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →